Healthcare Industry News: Angiotech Pharmaceuticals
News Release - October 9, 2006
GenVec Names Mark O. Thornton, MD, MPH, PhD as Senior Vice President, Clinical Development
GAITHERSBURG, Md.--(HSMN NewsFeed)--GenVec, Inc. (Nasdaq:GNVC ) announced today the appointment of Mark O. Thornton, MD, MPH, PhD as Senior Vice President, Clinical Development. Dr. Thornton was formerly Chief Medical Officer at ZIOPHARM, Inc., and most recently Managing Director, Clinical and Regulatory Affairs at Angiotech Pharmaceuticals. He also has over 6 years experience as a Medical Officer at the Food and Drug Administration (FDA) Center for Biologics (CBER).Dr. Thornton, a Clinical Pharmacologist and Trialist, has divided his 15-year career at FDA and in the biotechnology industry equally between oncology and infectious disease biologics clinical development. At the FDA, he was on the clinical review team for Erbitux® for its initial colon cancer indication, and Pegasys® for its Hepatitis C indication. At the FDA he also led the initial efforts to establish the FDA Gene Therapy Patient Tracking System and published on the topic of optimizing regulatory pathways for cancer vaccines. In industry, Dr. Thornton has performed Phase I-III clinical trials in both oncology and infectious disease settings, and successfully submitted PLAs for Certiva(TM) while at North American Vaccine and WinRho® while at Univax Biologics.
"Mark brings the experience and expertise to positively impact GenVec immediately," said GenVec's President and Chief Executive Officer Paul H. Fischer. "From getting drugs approved to designing, reviewing and analyzing clinical trials he has the skills we need to build value. His background in oncology and vaccines mesh perfectly with our product portfolio. I couldn't be happier about Mark's decision to join GenVec."
GenVec is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Additional information about GenVec and its portfolio of product candidates is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Source: GenVec
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
